Rating Change
JP Morgan analysts initiated coverage on Arcus Biosciences, Inc. (NYSE:RCUS) with a rating of Overweight on October 14, 2026.
new coverageNYSE:RCUS
JP Morgan Initiates Coverage on Arcus Biosciences, Inc. (RCUS) with Overweight
JP Morgan analysts initiated coverage on Arcus Biosciences, Inc. (NYSE:RCUS) with a rating of Overweight on October 14, 2026.
At publication ·
What changed
Arcus Biosciences, Inc. (NYSE:RCUS) · new coverage
- Firm
- JP Morgan
- Rating
- Overweight
- Price at event
- $22.53
- Market capitalization
- $2.7B
At a glance
Key takeaways
- JP Morgan initiated Overweight coverage on Arcus Biosciences (RCUS) on October 14, 2026, with the stock trading at $22.53 and a market cap of $2.7 billion.
Market Context
Arcus Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $22.53 with a market capitalization of $2.7B. The stock has gained 35.4% over the past 52 weeks.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arcus Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Arcus Biosciences, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Overweight | N/A |
| Sep 30, 2026 | Wedbush | Outperform | N/A |
| Sep 16, 2026 | TD Cowen | Buy | N/A |
| Sep 08, 2026 | Truist Securities | Buy | N/A |
| Aug 06, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RCUS Stock Page
Frequently Asked Questions
What does the Overweight rating mean for RCUS?
A rating of Overweight from JP Morgan reflects the analyst's outlook on Arcus Biosciences, Inc. (NYSE:RCUS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RCUS forecast page.